CTOR
Citius Oncology, Inc.
NASDAQ: CTOR · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
$1.03
-1.90% today
Updated 2026-09-28
Market cap
$111.05M
P/E ratio
—
P/S ratio
15.63x
EPS (TTM)
$-0.48
Dividend yield
—
52W range
$0 – $2
Volume
0.1M
WallStSmart proprietary scores
21
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C5.8
Quality
C+2.5
Profitability
F5.0
Valuation
C+4/9
Piotroski F-Score
Moderate
—
Altman Z-Score
—
—
Industry rank
—
View all highly rated stocks (75+) →261 stocks currently score above 75
Price targets
Analyst target
$4.00
+288.35%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
1 Strong Buy0 Buy0 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Debt/equity 0.25x — low leverage
Risks
- Thin margins at 0.00%
- Negative free cash flow $-4.85M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $7.11M |
| Net income | $-10.87M | $-12.70M | $-21.15M | $-24.76M | $-8.92M |
| EPS | — | — | — | — | $-0.48 |
| Free cash flow | $-47968.00 | $-601308.00 | $126349.00 | $-5.49M | $-4.85M |
| Profit margin | — | — | — | — | — |
Peer comparison
Smart narrative
Citius Oncology, Inc. trades at $1.03. Our Smart Value Score of 21/100 indicates the stock is weak. The company scores 4/9 on the Piotroski F-Score. TTM revenue stands at $7.11M.
Frequently asked questions
What is Citius Oncology, Inc.'s stock price?
Citius Oncology, Inc. (CTOR) trades at $1.03, on a P/S of 15.6x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Citius Oncology, Inc. overvalued?
Citius Oncology, Inc. carries a Smart Value Score of 21/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Citius Oncology, Inc. (CTOR)?
The 12-month analyst consensus target is $4.00, about 288.3% above the current $1.03. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is Citius Oncology, Inc.'s revenue?
Citius Oncology, Inc.'s trailing twelve-month revenue is $7.11M. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Company info
SectorHEALTHCARE
IndustryDRUG MANUFACTURERS - SPECIALTY & GENERIC
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio15.63x
ROE-120.53%
Beta3.53
50D MA$0.78
200D MA$0.88
Shares out0.11B
Float0.03B
Short ratio—
Avg volume0.1M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—